- Home
- FBP vs CELC Comparison
FBP vs CELC Comparison
Compare FBP & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FBP | CELC |
|---|---|---|
| Founded | 1948 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.1B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | FBP | CELC |
|---|---|---|
| Price | $21.25 | $102.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $23.67 | ★ $100.13 |
| AVG Volume (30 Days) | ★ 1.2M | 959.5K |
| Earning Date | 01-22-2026 | 11-12-2025 |
| Dividend Yield | ★ 3.40% | N/A |
| EPS Growth | ★ 13.12 | N/A |
| EPS | ★ 2.05 | N/A |
| Revenue | ★ $902,789,000.00 | N/A |
| Revenue This Year | $12.49 | N/A |
| Revenue Next Year | $4.57 | N/A |
| P/E Ratio | $10.33 | ★ N/A |
| Revenue Growth | ★ 3.91 | N/A |
| 52 Week Low | $16.40 | $7.58 |
| 52 Week High | $22.61 | $112.64 |
Technical Indicators
Market Signals| Indicator | FBP | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 64.68 | 62.67 |
| Support Level | $20.02 | $100.00 |
| Resistance Level | $21.32 | $112.64 |
| Average True Range (ATR) | 0.42 | 5.11 |
| MACD | 0.18 | -1.04 |
| Stochastic Oscillator | 86.10 | 33.16 |
Price Performance
Historical ComparisonAbout FBP First BanCorp. New
First BanCorp is a financial holding company. The company's operating segment includes Commercial and Corporate Banking; Mortgage Banking; Consumer (Retail) Banking; Treasury and Investments; United States Operations; and Virgin Islands Operations. It generates maximum revenue from the Consumer (Retail) Banking segment. The Consumer (Retail) Banking segment generates majority revenue, which consists of the Corporation's consumer lending and deposit-taking activities conducted mainly through its branch network and loan centres. Geographically, it derives a majority of revenue from Puerto Rico.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.